News

CytoRecovery Awarded National Science Foundation Phase II SBIR Research Grant

CytoRecovery, Inc., a leader in marker free technologies for the enrichment, sorting, and recovery of live cells, announced that the National Science Foundation (NSF) has approved its application to receive a Phase II SBIR Research Grant. Titled “Bioelectrical Cell Enrichment, Sorting, and Recovery with On-Chip Sample Prep and Monitoring,” the grant will provide $952,558 in research funding to develop new features that will be embodied in the Company’s next generation CytoR2 Platform for advanced cell sorting.

The research will be conducted in the laboratories of Dr. Rafael Davalos, Virginia Tech’s L. Preston Wade Professor of Biomedical Engineering, Dr. Nathan Swami, UVA Professor of Electrical and Computer Engineering, and the CytoRecovery laboratory located at the Virginia Tech Corporate Research Center (VT CRC) in Blacksburg, VA, under the direction of Dr, Alex Hyler, who is the Principal Investigator (PI) for the NSF grant.

“We are pleased to receive this prestigious SBIR research grant from the NSF and for the validation of our technology that it represents,” stated Dr. Hyler. She added, “As medicine moves towards personalized care, more precise cell recovery is required for research and pharmaceutical development, especially in the new fields of cell therapeutics and genomics. To address this challenge, we have brought to market our CytoR1 Platform – a label-free, fully-integrated product system for cell sorting, enrichment, and recovery.”

The funding will be used to advance features, progress software, and develop new technologies for marker free cell sorting, including integrating the processes of cell sample preparation and expanding capabilities to monitor cells in the Company’s proprietary, microfluidic chips.

Learn more here.

Recent News

12/11/2024

Liquet™ Medical Inc. Receives FDA 510(k) Clearance for the Versus™ Catheter

Liquet Medical Inc., a pioneering medical device company committed to advancing patient care through innovative technologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Versus™ Catheter. This innovative medical device is set to enhance the treatment of pulmonary artery blood clots by offering real-time pulmonary artery

12/03/2024

ivWatch Named to Inc.’s 2024 Best in Business List in Health Products Category

ivWatch, LLC, the IV safety company, is proud to announce it has been named to the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large.

12/03/2024

New Report Finds Bioscience Sector Generates Over $3 Trillion for U.S. Economy

The Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic performance, its impacts, and its geographic footprint. The report, “The U.S. Bioscience Economy: Driving Economic Growth and Opportunity in States and Regions,” analyzes the sector’s economic impact via employment, overall